|
Dr. Hamilton joined Avalon in August 2006 and is responsible for all clinical, medical, regulatory affairs and serves as the key contact with the Food and Drug Administration (FDA). Dr. Hamilton also participates in defining strategic clinical direction and development for the Company’s pipeline of products including AVN944 (Phase II), Beta Catenin Inhibitor (preclinical), and Aurora Pathway Inhibitor (preclinical). Dr. Hamilton brings to Avalon 20 years of expertise in the field of oncology. Most recently, from 2001-2006, he served as Group Director of Oncology, for GlaxoSmithKline. In this capacity he coordinated the oncology group's clinical activities from drug development through clinical trials including the regulatory process. Dr. Hamilton was responsible for the development and approval of BEXXAR, as well as the development of a number of other drug candidates including small molecules, antibodies and tumor vaccines. Dr. Hamilton was also actively involved in the evaluation of in-licensing drug candidates. From 1991-2001, Dr. Hamilton was the Director of Clinical Affairs in the Medical Oncology Branch of the National Cancer Institute where he oversaw the conduct of clinical investigations, was Director of the Medical Oncology Fellowship Program, and Chairman of the NCI IRB. Prior to that, 1985-1991, he was a Senior Investigator at the NCI’s Cancer Therapy Evaluation Program. Dr Hamilton is a board certified Oncologist and maintains faculty positions at the National Cancer Institute (NCI) and the National Naval Medical Center (Bethesda, MD). | 